Status
Conditions
Treatments
About
This study will examine how discounted vouchers for medical cannabis use affects opioid analgesic use in adults with chronic pain. Our study findings will have critically important implications to shape clinical care and medical cannabis policies.
Full description
This study will examine how discounted vouchers for medical cannabis use affects opioid analgesic use in adults with chronic pain. ReLeaf-V is a 4-arm blinded randomized controlled trial (RCT) of 352 adults with (a) severe or chronic neuropathic or joint pain, (b) opioid analgesic use, and (c) active certification for medical cannabis. We will randomize participants to a discounted voucher for: 1) a placebo soft-gel capsule product, 2) high THC:low CBD soft-gel capsule product (4.3mg THC/0.7mg CBD), 3) equal THC:CBD soft-gel capsule product (2.5mg THC/2.5mg CBD), or 4) low THC:high CBD soft-gel capsule product (0.2mg THC/4.8mg CBD). Over 14 weeks, participants will have 5 research visits in which data will be collected from questionnaires, and medical and Prescription Monitoring Program (PMP) records. The primary independent variable will be randomization arm, and the primary outcome will be cumulative opioid analgesic dose.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
To maintain the integrity of the study, we do not disclose all inclusion criteria to potential participants.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
270 participants in 4 patient groups, including a placebo group
Loading...
Central trial contact
Stephen Dahmer, MD; Olivia Uhley, BA
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal